Invivyd
Biologics & Biosimilars · Infectious Disease Therapeutics

Invivyd: Funding & valuation

Invivyd: 3 money records, each linked to its source.

Data updated Nov 20, 2026 · Back to the company report

Financials

Revenue of $53.4M in 2025. +110.5% on the year before. Net income −$52.5M.

$53.4MRevenue2025 · +110.5%
−$52.5MNet income2025 · +69.1%
Revenue by yearas filed, with the net income
2025$53.4Mnet income −$52.5M
2024$25.4Mnet income −$169.9M
2023$0net income −$198.6M
Sources: SEC

Money

Invivyd: 3 money records, each linked to its source.

$155kCapital expenditureFY2025
From its filingssec.gov ↗
FY2023FY2024FY2025
Shares bought back$1k––
Capital expenditure$615k$140k$155k
Stock-based compensation$18.7M$19.8M$11.6M
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".